Active substance
Results for the substance elvitegravir+cobicistat+emtricitabine+tenofovir
1 result
About this active substance
Elvitegravir, cobicistat, emtricitabine, and tenofovir are antiviral medications used in combination to treat HIV-1 infection. This combination, available as a single daily tablet, is designed to suppress HIV replication and maintain a healthy immune system.
Elvitegravir is an integrase inhibitor that prevents the integration of viral DNA into host cells, a critical step in the HIV life cycle. Cobicistat has no direct antiviral activity but acts as a pharmacokinetic enhancer, boosting the effectiveness of elvitegravir by inhibiting its metabolism.
Emtricitabine and tenofovir are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that block reverse transcriptase, an enzyme essential for HIV replication. These two components prevent the virus from multiplying, reducing the viral load in the blood and slowing disease progression.
This combination is well-tolerated by most patients, but side effects such as nausea, diarrhea, headache, or fatigue may occur. In rare cases, more serious adverse effects, such as kidney dysfunction or decreased bone density, may develop, making regular monitoring essential.
Treatment with this combination does not cure HIV infection but helps suppress the virus to undetectable levels, reducing the risk of transmission and improving patients' quality of life. It is crucial to take the medication daily as prescribed to prevent the development of viral resistance.
Elvitegravir is an integrase inhibitor that prevents the integration of viral DNA into host cells, a critical step in the HIV life cycle. Cobicistat has no direct antiviral activity but acts as a pharmacokinetic enhancer, boosting the effectiveness of elvitegravir by inhibiting its metabolism.
Emtricitabine and tenofovir are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that block reverse transcriptase, an enzyme essential for HIV replication. These two components prevent the virus from multiplying, reducing the viral load in the blood and slowing disease progression.
This combination is well-tolerated by most patients, but side effects such as nausea, diarrhea, headache, or fatigue may occur. In rare cases, more serious adverse effects, such as kidney dysfunction or decreased bone density, may develop, making regular monitoring essential.
Treatment with this combination does not cure HIV infection but helps suppress the virus to undetectable levels, reducing the risk of transmission and improving patients' quality of life. It is crucial to take the medication daily as prescribed to prevent the development of viral resistance.